Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05552976
Title A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)
Acronym SUCCESSOR-2
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ROU | NOR | NLD | ITA | ISR | HUN | GRC | GBR | ESP | DNK | DEU | CAN | BRA | BGR | AUT | AUS | ARG


No variant requirements are available.